Glucose-6-Phosphate Dehydrogenase Deficiency

Last updated: March 25, 2026

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive condition that is characterized by reduced levels of the antioxidant NADH. This deficiency makes red blood cells susceptible to oxidative stress, causing hemolysis, which can be triggered by certain infections, drugs, and foods.

G6PD deficiency is the most common human enzyme deficiency.

WHO classification of G6PD variants

ClassDescriptionFeatures
Class ISevere enzyme deficiencyChronic hemolysis
Class IISevere enzyme deficiency (1-10% residual activity)Intermittent acute hemolysis
Class IIIModerate enzyme deficiency (10-60% residual activity)Intermittent acute hemolysis
Class IVNo enzyme deficiency (60-150% activity)
Class VIncreased enzymatic activity (>150%)
  • Causes of acute hemolysis in G6PD deficiency
    • Infections
    • Acute illness, e.g. DKA
    • Fava beans
    • Henna
    • Drugs
      • Antimalarial drugs: chloroquine, primaquine
      • Sulfa drugs (TMP-SMX)
      • Nitrofurantoin
      • Isoniazid
      • Dapsone
      • NSAIDs
      • Ciprofloxacin
      • Chloramphenicol
  • Pathophysiology
    • G6PD is the rate-limiting enzyme of the HMP pathway, which yields NADPH
    • NADPH convertS oxidized glutathionine back to reduced glutathione
    • Reduced glutathione is capable of neutralizing reactive oxygen species and free radicals, therefore protecting RBCs from oxidative damage.
    • G6PD deficiency → reduced glutathione → red blood cells become susceptible to oxidative stress → oxidized hemoglobin forms heinz bodies, which compromise membrane integrity and flexibility; reactive oxygen species damage the red cell membrane → intravascular and extravascular hemolysis
  • Patient History
    • Male
    • African, Middle Eastern, asian or Mediterranean heritage
    • History of exposure to oxidants
    • History of infection or acute illness
  • Signs and symptoms
    • Asymptomatic
    • Recurring hemolytic crises in response to oxidative stress
      • Sudden onset of back or abdominal pain
      • Jaundice
      • Dark urine due to hematuria or hemoglobinuria
      • Transient splenomegaly
    • Recurrent severe infections cause symptoms of chronic granulomatous disease
  • Differentials
  • Investigations
    • Peripheral blood film
      • Contracted and fragmented cells
      • Heinz bodies – denatured and precipitated hemoglobin, which appear as purple spots
      • Bite cells and Blister cells – formed when Heinz bodies are removed by splenic macrophages
    • Normocytic anemia
    • Increased reticulocyte count
    • Increased unconjugated bilirubin
    • Increased LDH
    • Decreased haptoglobin
    • Hemoglobinuria
    • Qualitative measurement of G6PD enzymatic activity (fluorescent spot test) for screening
    • Quantitative G6PD enzyme analysis to confirm the diagnosis
    • Genetic testing for the G6PD gene mutation
  • Treatment
    • Educate the patient
    • Stop or avoid the offending drugs and food
    • Promptly treat infection or illness
    • Adequate hydration +/- oxygen in case of severe hemolysis
    • Blood transfusion in severe cases
    • Phototherapy or exchange transfusion for neonatal jaundice
    • Splenectomy may be performed to reduce the frequency of crises
    • Genetic counselling for affected individuals and their families
  • Complications
    • Haemolytic anaemia
    • Neonatal jaundice
    • Overwhelming post-splenectomy infection
    • Methaemoglobinaemia
    • Chronic nonspherocytic hemolytic anaemia
    • X-linked mental retardation
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *